About Alaunos Therapeutics, Inc.
https://www.alaunos.comAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies.
CEO
Holger Weis CPA
Compensation Summary
(Year 2018)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-07-18 | Reverse | 1:10 |
| 2024-02-01 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:3.62M
Value:$9.92M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:3.1M
Value:$8.51M
BELMONT GLOBAL ADVISORS, INC.
Shares:2.23M
Value:$6.1M
Summary
Showing Top 3 of 77
About Alaunos Therapeutics, Inc.
https://www.alaunos.comAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.19M ▲ | $-1.16M ▼ | 0% | $-0.55 ▲ | $-1.16M ▼ |
| Q2-2025 | $0 ▼ | $854K ▼ | $-1.05M ▲ | 0% ▲ | $-0.63 ▲ | $-1.04M ▲ |
| Q1-2025 | $2K ▼ | $1.09M ▲ | $-1.07M ▼ | -53.65K% ▼ | $-0.67 ▼ | $-1.07M ▼ |
| Q4-2024 | $4K ▲ | $759K ▼ | $-742K ▲ | -18.55K% ▼ | $-0.46 ▲ | $-742K ▲ |
| Q3-2024 | $0 | $1.15M | $-1.13M | 0% | $-0.7 | $-1.13M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.94M ▼ | $3.72M ▼ | $921K ▼ | $2.8M ▼ |
| Q2-2025 | $2.88M ▲ | $4.74M ▲ | $1.07M ▲ | $3.66M ▲ |
| Q1-2025 | $319K ▼ | $2.12M ▼ | $1.06M ▲ | $1.06M ▼ |
| Q4-2024 | $1.09M ▼ | $2.75M ▼ | $692K ▼ | $2.06M ▼ |
| Q3-2024 | $1.68M | $3.55M | $826K | $2.72M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.16M ▼ | $-844K ▼ | $-97K ▼ | $0 ▼ | $-941K ▼ | $-941K ▼ |
| Q2-2025 | $-1.05M ▲ | $-701K ▲ | $0 | $3.26M ▲ | $2.56M ▲ | $-701K ▲ |
| Q1-2025 | $-1.07M ▼ | $-772K ▼ | $0 | $0 | $-772K ▼ | $-772K ▼ |
| Q4-2024 | $-742K ▲ | $-592K ▲ | $0 | $0 | $-592K ▲ | $-592K ▲ |
| Q3-2024 | $-1.13M | $-781K | $0 | $0 | $-780K | $-781K |
CEO
Holger Weis CPA
Compensation Summary
(Year 2018)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-07-18 | Reverse | 1:10 |
| 2024-02-01 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:3.62M
Value:$9.92M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:3.1M
Value:$8.51M
BELMONT GLOBAL ADVISORS, INC.
Shares:2.23M
Value:$6.1M
Summary
Showing Top 3 of 77